Advertisement
Research Article Free access | 10.1172/JCI109240
Find articles by Brandeis, W. in: JCI | PubMed | Google Scholar
Find articles by Helson, L. in: JCI | PubMed | Google Scholar
Find articles by Wang, Y. in: JCI | PubMed | Google Scholar
Find articles by Good, R. in: JCI | PubMed | Google Scholar
Find articles by Day, N. in: JCI | PubMed | Google Scholar
Published December 1, 1978 - More info
The presence of circulating immune complexes (ICS) in freshly drawn sera of 67 children with neuroblastoma was studied by the Raji cell radioimmunoassay of Theofilopoulos et al. (J. Clin. Invest. 57: 169--182), with particular emphasis on the correlation of levels of ICS with stage of disease and changes attributable to treatment. There was a close correlation between amount of complexes and stage of disease and treatment. Levels of ICS increased as the stage of the disease advanced, and were significantly higher (P less than 0.005) in stage IV than in all other stages combined. When patients with stage IV disease were subdivided into "before," "during," and "after" treatment groups, there was a significant decrease in ICS levels as treatment progressed. Studies of complement and complement components did not give such a clear relationship. A significant decrease of hemolytic C1 values was found in patients with "active disease" compared to normal age-matched controls. Some high C3 levels, determined immunochemically, were associated with low hemolytic levels of C3, which were attributed to C3 cleavage detected by immunoelectrophoresis. Based on our survival data, ICS, which were significantly different in 20 patients now decreased when compared to those of other patients, are very valuable in the prognosis of neuroblastoma.